Daehan Pharmaceutical대한약품
023910 · KOSDAQ · ₩023910 · 대한약품
₩24,900▼ ₩300 (1.19%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 29.6% | 31.1% | 34.2% | 33.6% | 32.7% | 32.7% |
| Operating margin | 13.9% | 14.9% | 18.6% | 18.3% | 17.9% | 17.0% |
| Net margin | 13.0% | 13.3% | 16.5% | 14.5% | 13.5% | 13.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +3.8% | +2.2% | +4.2% | +6.3% | +7.5% | — |
| Operating income growth | −3.3% | −18.1% | +6.4% | +8.6% | +13.4% | — |
| Net income growth | +2.0% | −18.1% | +18.8% | +13.9% | +10.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 9.3% | 9.6% | 12.9% | 12.0% | 11.7% | 11.2% |
| Return on assets | 8.0% | 8.2% | 10.9% | 10.0% | 9.1% | 8.3% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 16.6% | 15.8% | 17.5% | 18.7% | 22.9% | 34.4% |
| Net debt to equity | — | — | — | −40.9% | −37.4% | −29.7% |
| Current ratio | 397.3% | 364.3% | 322.1% | 387.2% | 365.2% | 319.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Daehan Pharmaceutical / 대한약품 / 023910 / KRX:023910
Source: KRX statistical information